EMBL Australia group leader A/Prof Mikaël Martino and Victorian node head Prof Peter Currie will use a grant of more than $820,000 from the Medical Research Future Fund's Stem Cell Therapies Mission to improve the lives of those with muscular dystrophies & myopathies.
Two EMBL Australia group leaders have been awarded close to $2 million in funding for their innovative projects under the Australian Research Council’s Future Fellowships scheme.
New research from an EMBL Australia group leader outlines a novel method of enhancing regenerative activity, with clinical implications on improving the effectiveness of growth factor-based therapies.
EMBL Australia group leader Professor David Lynn will be the interim director of a new $7 million state-of-the-art centre for genomics in South Australia that he played a vital role in championing.
The international research community is collaborating on a scale and at a speed never seen before to battle COVID-19 and EMBL Australia group leaders have answered the call to help.
Professor David Lynn is an EMBL Australia Group Leader, based at the South Australian Health and Medical Research Institute (SAHMRI), and a Flinders University Professor.
EMBL Australia group leader Max Cryle has provided a new understanding of Glycopeptide antibiotics (GPAs) biosynthesis that allows new GPAs to be made and tested in the laboratory - a vital step in the quest to develop new antibiotics to keep pace with the ever-evolving ‘superbugs’ that threaten global public health.
An opinion article by EMBL Australia Scientific Head Professor James Whisstock (published in The Herald Sun on 13 May 2020) calls for a national approach for funding a diversity and depth of scientific research we hope we might never need.
EMBL Australia group leader Professor Eduardo Eyras has developed a general-purpose tool to study how cells function in a common type of brain tumour, but that could also be applied to other tumours and diseases. The research was published in Nature Communications.
